Clinical Trials Logo
  1. Home
  2. Infectious Mononucleosis
  3. NCT02463669

The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department

Splenomegaly Clinical Trial

Official title:
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department

Clinical Trial Summary

The purpose of this study is to determine if splenomegaly on point-of-care ultrasound (POCUS) is an accurate and user-friendly surrogate to the heterophile antibody test and Epstein-Barr Virus (EBV) serologies to diagnose acute mononucleosis infection in patients presenting with sore throat to the Emergency Department (ED).

Clinical Trial Description

The investigators seek to determine whether the presence of splenomegaly on POCUS can accurately diagnose acute infectious mononucleosis in symptomatic ED patients, and determine the feasibility of performing point-of-care ultrasound for splenomegaly by emergency physicians in the emergency department setting. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02463669
Study type Observational
Source Jewish General Hospital
Contact
Status Terminated
Phase
Start date April 2016
Completion date October 4, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Completed NCT04430881 - A National Study in Patients With Unexplained Splenomegaly
Completed NCT01948076 - Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination N/A
Completed NCT04716166 - Incentive Spirometry and Upper Abdominal Laparoscopic Surgery N/A
Completed NCT01907932 - Estimation of Spleen by Residents With VScan N/A
Recruiting NCT03801434 - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Phase 2
Terminated NCT02421354 - Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Phase 2
Recruiting NCT05641103 - PREDIGA 2: Spanish Acronym of "Educational and Diagnostic Project for Gaucher and ASMD"
Completed NCT01810419 - Ultrasound Estimation of Spleen Size N/A
Recruiting NCT01201655 - Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis N/A
Active, not recruiting NCT02871219 - Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Phase 2
Completed NCT00006148 - Spleen Size in Peripheral Blood Stem Cell Donors N/A
Withdrawn NCT01331642 - Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
Withdrawn NCT02298699 - Biomarker for Sly Disease (MPS VII) (BioSly)
Withdrawn NCT02298634 - Biomarker for Farber Disease (BioFarber)
Terminated NCT02730884 - Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Phase 2